ALUNBRIG brigatinib

Drug Class

ALK tyrosine kinase inhibitor

Mechanism

Brigatinib inhibits autophosphorylation of ALK and ALK-mediated phosphorylation of downstream signaling proteins, halting tumor growth.

Approved Indication

Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).

What This Means For Patients

Alunbrig (brigatinib) is a targeted ALK kinase inhibitor used to treat ALK-positive metastatic non-small cell lung cancer. It helps block abnormal protein signals that cause cancer cells to grow and spread. While approved in China in 2022, it remains clinically accessible via the Lecheng pilot zone's special import channel.

Regulatory Approvals

• FDA — approved (2017) — label
• EMA — approved (2018) — source
• NMPA — approved (2022) — source

Pivotal Clinical Evidence

• ALTA-1L — Camidge et al., N Engl J Med 2018 (NCT02737501) — DOI

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208756s003lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig
• https://doi.org/10.1056/NEJMoa1810171